Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
Aarati Rao, Naynesh Kamani, Alexandra Filipovich...
https://pubmed.ncbi.nlm.nih.gov/16990602/Actively Recruiting
Led by Washington University School of Medicine · Updated on 2026-09-16
220
Participants Needed
28
Research Sites
260 weeks
Total Duration
Researchers are studying a reduced-intensity preparative regimen for hematopoietic stem cell transplantation in children and young adults with non-malignant disorders. The goal is to achieve donor cell engraftment using immune suppression without radiation or high-dose chemotherapy, aiming to reduce early and late toxicities. The study also evaluates toxicities within the first 100 days post-transplant and aims to lower rates of acute and chronic graft-versus-host disease GVHD through specific GVHD prevention methods. Participants receive one of several reduced-intensity conditioning treatment plans depending on their disease and donor matching. These regimens include hydroxyurea, Campath-1H, fludarabine, melphalan, and sometimes thiotepa, followed by hematopoietic stem cell infusion. GVHD prophylaxis is provided with different drug schedules for bone marrow or cord blood recipients, including tacrolimus or cyclosporine, mycophenolate mofetil, abatacept, and methotrexate. Treatment timing spans from about 50 days before transplant through various post-transplant days. During the study, participants undergo assessments to measure donor engraftment, blood counts, and toxicities at 100 days and longer-term outcomes such as chronic GVHD, immune system recovery, and survival up to two years after transplant. Researchers monitor toxicity grades and chimerism to evaluate treatment impact. The study involves follow-up laboratory tests, clinical evaluations, and GVHD assessments to understand both short- and long-term effects of the conditioning regimens and transplant outcomes.
CONDITIONS
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
L
Lissy Keller, CCRP
I
Ian Snyder, CCRP
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Washington University School of Medicine
Lead Sponsor
St. Louis Children's Hospital
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Non-thalassemia, non-hemoglobinopathy—8/8 HLA-matched bone marrow transplant | Thalassemia—matched BM or mismatched UCB transplant | Hemoglobinopathy—mismatched BM or UCB transplant | Non-hemoglobinopathy—mismatched BM or UCB transplant |
|---|---|---|---|---|
| What it is | Reduced-intensity conditioning regimen consisting of Campath (alemtuzumab), fludarabine, and melphalan followed by hematopoietic stem cell transplantation (HSCT) using an 8/8 HLA-matched bone marrow (BM) donor. | Reduced-intensity conditioning with Campath, fludarabine, melphalan, and thiotepa (Campath/Flu/Mel/Thiotepa) followed by HSCT from an 8/8 HLA-matched BM or 5–8/8 HLA-matched umbilical cord blood donor. | Reduced-intensity conditioning (Campath/fludarabine/melphalan/thiotepa) followed by HSCT from a 7/8 HLA-matched BM or 5–8/8 HLA-matched umbilical cord blood donor for children with hemoglobinopathy. | Reduced-intensity conditioning (Campath/fludarabine/melphalan/thiotepa) followed by HSCT from a 7/8 HLA-matched BM or 5–8/8 HLA-matched umbilical cord blood donor for children with non-malignant, non-hemoglobinopathy disorders. |
| Role in trial | Assigned to eligible patients with non-thalassemia, non-hemoglobinopathy disorders and a fully matched bone marrow donor. | Assigned to eligible thalassemia patients with a matched BM or mismatched cord blood donor. | Assigned to children and young adults with hemoglobinopathies and a mismatched BM or cord blood donor. | Assigned to those with non-hemoglobinopathy, non-malignant disorders and a mismatched BM or cord blood donor. |
| Primary use/purpose | Conditioning children and young adults with non-malignant disorders (excluding thalassemia, hemoglobinopathies) for allogeneic HSCT with a matched BM donor, aiming to achieve donor engraftment with reduced regimen-related toxicity. | Pre-transplant conditioning for thalassemia patients to receive a matched BM or mismatched UCB transplant, designed to maximize engraftment and minimize toxicity. | Pre-transplant conditioning for pediatric hemoglobinopathy cases undergoing mismatched BM or cord blood transplantation, seeking successful engraftment with lower regimen toxicity. | Pre-transplant conditioning for non-hemoglobinopathy, non-malignant disorders with mismatched BM or UCB transplantation, designed for donor engraftment with less treatment-related toxicity. |
| How it is given or performed | Campath (IV or subcutaneous), fludarabine (IV), and melphalan (IV) are administered before HSCT from a fully matched marrow donor. GVHD prevention regimen as per protocol. | Campath, fludarabine, melphalan, and thiotepa are administered over several days before HSCT from a matched BM or mismatched UCB donor. GVHD prophylaxis per assigned regimen. | Campath, fludarabine, melphalan, and thiotepa are administered before HSCT from a mismatched BM or cord blood donor. GVHD prevention regimen is applied as per protocol assignment. | Campath, fludarabine, melphalan, and thiotepa are given to patients before mismatched BM or UCB transplant. GVHD prevention protocol applies as assigned. |
| Evidence status | Evidence from single-arm studies and case series supports the feasibility of reduced-intensity conditioning (RIC) with Campath/fludarabine/melphalan for donor engraftment and reduced toxicity in non-malignant disorders, but controlled trial data are limited. | Retrospective and prospective studies indicate that Campath/fludarabine/melphalan/thiotepa can enable donor engraftment with some reduction in transplant toxicity for thalassemia, especially in high-risk or mismatched donor cases, but robust comparative data are lacking. | Published data from single-arm studies in pediatric hemoglobinopathies show that reduced-intensity regimens with Campath, fludarabine, melphalan, and thiotepa can result in successful donor engraftment. Long-term randomized comparative effectiveness remains unclear. | Reports suggest feasibility of engraftment with this reduced-intensity approach in non-hemoglobinopathy disorders, but controlled data are sparse and long-term outcomes for mismatched donors remain uncertain. |
| Important limitations | Lack of direct comparator group; long-term survival, GVHD, and late toxicity outcomes still need robust evaluation in large-scale or randomized trials. Most evidence is based on institutional or single-arm studies. | No direct randomized comparator; applicability in all thalassemia and donor combinations is uncertain; long-term data limited for high-risk or mismatched settings. | Outcomes difficult to generalize without randomized control; follow-up data for relapse, graft failure, and late toxicities are still limited for these mismatched donor settings. | Evidence consists mainly of single-institution experience and small patient samples; difficult to draw general conclusions for uncommon non-hemoglobinopathy, mismatched conditions. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 50 days before transplant through 1 year post-transplant
Participants receive a reduced-intensity conditioning regimen with drugs such as hydroxyurea, Campath-1H, fludarabine, melphalan, and sometimes thiotepa, followed by hematopoietic stem cell infusion. GVHD prevention drugs are given according to donor type.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Aarati Rao, Naynesh Kamani, Alexandra Filipovich...
https://pubmed.ncbi.nlm.nih.gov/16990602/Allison A King, Naynesh Kamani, Nancy Bunin...
https://pubmed.ncbi.nlm.nih.gov/26348869/S Shenoy, W J Grossman, J DiPersio...
https://pubmed.ncbi.nlm.nih.gov/15592491/D Bhatla, S M Davies, S Shenoy...
https://pubmed.ncbi.nlm.nih.gov/18500373/M D Hansen, A H Filipovich, S M Davies...
https://pubmed.ncbi.nlm.nih.gov/18026148/Washington University School of Medicine
Lead Sponsor
St. Louis Children's Hospital
Collaborating Sponsor